Selective CDK2 Inhibitors for CDK4/6 Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for tumors, particularly those resistant to CDK4/6 inhibitors, are challenged by the amplification of CCNE1 and increased CDK2 activity, leading to resistance and insensitivity, necessitating the development of highly active and specific CDK2 inhibitors.
Innovation Solution
A compound of formula (I) or (II) or their pharmaceutically acceptable salts, stereoisomers, or deuterides, which selectively inhibit CDK2, are developed to target CDK2 activity and potentially reverse resistance to CDK4/6 inhibitor treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CDK4/6 inhibitors are used for tumor treatment, then clinical efficacy is improved, but resistance develops due to CCNE1 amplification and increased CDK2 activity
Solution Approach 1:
The patent introduces a CDK2 inhibitor as an intermediary agent to counteract the resistance mechanism. The CDK2 inhibitor specifically targets and inhibits CDK2 activity, which is upregulated due to CCNE1 amplification, thereby reversing the resistance to CDK4/6 inhibitors and restoring treatment efficacy.
Solution Approach 2:
The patent changes the therapeutic parameter by shifting from solely inhibiting CDK4/6 to also inhibiting CDK2. This parameter change addresses the resistance mechanism by targeting the downstream effect of CCNE1 amplification (increased CDK2 activity), thereby overcoming treatment failure.
2Productivity
If CDK2 activity is increased due to CCNE1 amplification, then cell proliferation is promoted, but treatment response to CDK4/6 inhibitors is reduced
Solution Approach 1:
The CDK2 inhibitor serves as an intermediary that specifically targets the CDK2 enzyme, which is overactive due to CCNE1 amplification. By inhibiting CDK2, the patent blocks the proliferative signal while simultaneously reversing the resistance to CDK4/6 inhibitors, thereby improving treatment response despite high cell proliferation potential.
Solution Approach 2:
The patent changes the therapeutic approach by adding CDK2 inhibition to the treatment regimen. This parameter change directly addresses the molecular driver (CCNE1 amplification leading to increased CDK2 activity) that is causing both high proliferation and treatment resistance, thereby improving treatment response.
3Measurement precision
If selective CDK2 inhibitors are developed, then specificity for CDK2 is improved, but development complexity increases
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular characteristics that target the unique structural features of the CDK2 active site. The compounds are engineered to interact specifically with residues in the CDK2 binding pocket, achieving high selectivity for CDK2 over other CDK family members through localized molecular interactions.
Data Source
AI summary
A CDK2 inhibitor and a preparation method therefor, and a pharmaceutical composition. The present invention further relates to a use of the compound or the pharmaceutical composition in preparation of drugs for preventing or treating related diseases mediated by CDK2, wherein the diseases comprise abnormal cell growth.